60 search results for: symptoms

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).

expert video

What Could Remission Mean in AD?

1 min

Dermatology

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

10 min

Dermatology

Learn more about the guideline-based diagnosis of chronic spontaneous urticaria with this interactive patient case.

expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

1 min

Dermatology

Explore the impact of moderate-to-severe atopic dermatitis on sleep in pediatric patients – a short soundbite from EADV 2022.

expert video

The Clinical Presentation of CSU is Heterogeneous

3 min

Dermatology

Dr Hawkes provides an overview of the distinctive characteristics of wheals and angioedema in clinical manifestation

expert video

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

12 min

Dermatology

Dr. Stephan Weidinger describes the roles of IL-4 and IL-13 in skin barrier dysfunction, and the potential of early control of type 2 inflammation to modify disease course. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.

expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

3 min

Dermatology

Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

expert video

Comorbidities and Clinical Management in CSU

4 min

Dermatology

In their interview Drs. Maurer and Ensina highlight the understanding of comorbidities in CSU is important in clinical management.

expert video

Comorbidities and Disease Burden in CSU

10 min

Dermatology

In their interview Drs. Maurer and Ensina shed light on the significant burden of comorbidities in CSU.

interactivity

Prurigo Nodularis: The Patient Journey

5 min

Dermatology

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.

expert video

GOLD Diagnosis and Assessment of COPD

4 min

Pulmonology

This short video presentation outlines the diagnosis and assessment of COPD according to the GOLD report, focusing on clinical features and assessment goals.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PolandChange country/region